ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Halozyme Therapeutics Incorporated

Halozyme Therapeutics Incorporated (HALO)

54.34
0.30
(0.56%)
Closed July 22 4:00PM
54.34
0.00
( 0.00% )
Pre Market: 4:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
54.34
Bid
53.25
Ask
55.91
Volume
2
0.00 Day's Range 0.00
32.83 52 Week Range 55.82
Market Cap
Previous Close
54.34
Open
-
Last Trade
2
@
54.5
Last Trade Time
04:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
1,298,425
Shares Outstanding
127,274,000
Dividend Yield
-
PE Ratio
24.56
Earnings Per Share (EPS)
2.21
Revenue
829.25M
Net Profit
281.59M

About Halozyme Therapeutics Incorporated

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeut... Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Halozyme Therapeutics Incorporated is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker HALO. The last closing price for Halozyme Therapeutics was $54.34. Over the last year, Halozyme Therapeutics shares have traded in a share price range of $ 32.83 to $ 55.82.

Halozyme Therapeutics currently has 127,274,000 shares outstanding. The market capitalization of Halozyme Therapeutics is $6.92 billion. Halozyme Therapeutics has a price to earnings ratio (PE ratio) of 24.56.

Halozyme Therapeutics (HALO) Options Flow Summary

Overall Flow

Bullish

Net Premium

171k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

HALO Latest News

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire SAN DIEGO, June 25, 2024 OCREVUS®...

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO, June 21, 2024...

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook PR Newswire SAN DIEGO, June 6, 2024 Company Granted New European Patent for ENHANZE® Drug Delivery Platform...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.442.7221172022752.955.8252.55114014754.60463333CS
41.853.524480853552.4955.8250.68128330452.91495095CS
1215.840.996367410538.5455.8237.965129842548.69101392CS
2620.1458.888888888934.255.8233.15115256943.67454609CS
5211.6227.200374531842.7255.8232.83110890441.14168625CS
15611.6127.170606131542.7359.4629.85112785641.66499528CS
26037.85229.53305033416.4959.4612.71121545936.04743663CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NMHINatures Miracle Holding Inc
$ 0.9691
(176.89%)
5.79M
GPGreenPower Motor Company Inc
$ 1.79
(59.11%)
4
FEIMFrequency Electronics Inc
$ 13.34
(32.08%)
77.65k
LGHLWLion Group Holding Ltd
$ 0.0093
(30.99%)
156
ENGENGlobal Corp
$ 2.22
(29.82%)
258
RNAZTransCode Therapeutics Inc
$ 0.3173
(-59.96%)
284.54k
MIRAMIRA Pharmaceuticals Inc
$ 3.58
(-28.54%)
745.72k
CMAXCareMax Inc
$ 3.95
(-23.89%)
249.49k
NUKKNukkleus Inc
$ 0.3943
(-20.82%)
127.08k
XCURExicure Inc
$ 0.4128
(-17.41%)
5.59k
NMHINatures Miracle Holding Inc
$ 0.9691
(176.89%)
5.79M
LIFWMSP Recovery Inc
$ 0.6221
(22.77%)
2.96M
BREABrera Holdings PLC
$ 0.682
(-7.48%)
1.55M
SLNASelina Hospitality PLC
$ 0.0353
(-4.59%)
1.04M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.52
(1.61%)
1M

HALO Discussion

View Posts
OncoJock OncoJock 13 hours ago
Nice. Thanks for sharing.

-- OJ
👍️0
biotechinvestor1 biotechinvestor1 4 days ago
Another nice find. Well done!
👍️ 2
maumar maumar 4 days ago
You are welcome.

A new trial:
https://clinicaltrials.gov/study/NCT06503731?term=NCT06503731&rank=1
👍️ 3
OncoJock OncoJock 5 days ago
Great analysis and commentary. Thank you so much for sharing your expertise with us.

I, personally, am not familiar with the patent intricacies so it's great to hear from a fellow shareholder who is.

My specialty is writing about the latest and greatest forms of cancer medicine, and I'm keenly aware of the competition for market share in certain therapeutic settings among Big Pharmas like J&J, Merck, BMS, Roche, AbbVie, etc. So this is why I'm so bullish on Halo, because I see Enhanze as a way for Big Pharmas to grab market share from each other. It's like Halo sells bullets to armies on both sides of the war, and there's no cease-fire in sight. I just wish more analysts had a similarly bullish perspective.

-- OJ
👍️ 1
stockrafter stockrafter 5 days ago
Thanks, but not much of a find when one knows where and when to look for new filing and patent postings

A side note, with the ease of using HVAI over IV, there is no doubt the HVAI will be used for multiple injections throughout the day or week to provide a more steady state conc. of drugs in the body, which is noted in several patents/filings related to Enhanze......also hinted at by Dr Torley.....just get it done.....
👍️ 1
biotechinvestor1 biotechinvestor1 5 days ago
Great find! Thank you
👍️0
stockrafter stockrafter 5 days ago
Another of many product filings they keep pushing out after getting a patent (#3)......but why...

Start marketing the products.....start making money for all the detailed effort....or stop wasting investors money spinning your wheels......IMO........

Oh well go HALO, do just fine as of late.......waiting for the big 60............

Today's new filing........ https://www.freepatentsonline.com/y2024/0238311.html

Listed are all 10 product filings and all 11 filings for the injector.

1 US20240238311 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

2 US20240131035 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

3 11857555 Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
Aqueous hydrocortisone sodium phosphate and monothioglycerol formulations are disclosed.

4 JP2023542345A Hydrocortisone sodium phosphate and monothioglycerol aqueous pharmaceutical formulation
Aqueous hydrocortisone sodium phosphate and monothioglycerol formulations are disclosed. [

5 WO/2023/183807A1 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

6 US20230302016 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

7 EP4213827A1 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

8 US20230099165 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

9 US20220096496 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

10 WO/2022/061303A1 AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL

👍️ 1
maumar maumar 5 days ago
I would think Halo gets royalties from all territories, including China. What makes you think they may not?

I hope you are right about multiple new deals but it's hard for me to be so optimistic. I don't know why deals have become smaller and far in between in the past several years but I don't quite see why the EU patent extension will make it easier to sign new partnerships. It's also hard for me to blame Helen. She signed partnerships with the likes of Janssen, Lilly, Abbvie as early as 2014. I can't believe she has become completely inept. Also, Enhanze is not a hidden gem that needs better marketing. Even before her tenure, Halo had partnerships with Roche and Pfizer. Enhanze has been around for a long time and everybody knows about it. Unfortunately, the simplest explanation is probably the correct one: demand is not what it used to be.

Honestly, I have no idea why they haven't been able to capitalize on the success of Darzalex SC and why some of their partnerships have been fruitless. I expected they would have 30-40 Enhanze products in development by now but it hasn't happened. I also don't understand why Alteogen was able to create a "standalone" of Enhanze. Couldn't Halo do the same thing? Could they still do it?

I agree that analysts and money managers are waiting for new deals. If they are unable to sign significant new partnerships in the next few months, though, Halo needs to stop the stock buybacks and focus on M&A, the sooner the better, imho.

Current PPS is still more than $5 shy of all time highs mainly for one reason: the clause in their agreement with Janssen about the royalty step-down. JNJ reported Darzalex sales today. Here is a note from JPM:

"Our Take: Ahead of Genmab’s detailed Q2’24 results on August 1st, JNJ has reported Q2’24 Darzalex sales of $2,878m, 3% ahead of company consensus and 3% ahead of JPMe, with the beat vs. JPMe driven by US sales of $1,641m, which came in 6% ahead , with ex US sales of $1,237m, which was in line. Based on this update, we expect Genmab to modestly upgrade its 2024 Darzalex sales guidance to $11,100m-11,500m (from: $10,900m-11,500m), which should underpin consensus expectations at $11,259m."

I think the above illustrates how massively important Darzalex and that clause are to Halo. At a 4% royalty rate, Halo is likely to get over $400M in royalties in 2024 (guidance for total royalties is $520-555). Best case scenario is that Halo gets the same patent extension in US and so Halo's royalties will be cut in half in 2029 and end in 2032. The same will happen for the royalties from Amivantamab. By 2029 Darzalex SC and Amivantamab SC sales will probably be over $20B.

Without that clause, I would think Halo's PPS would be at least $80 now.
👍️ 2
Fred Kadiddlehopper Fred Kadiddlehopper 6 days ago
I wonder if the China deal will result in revenue for HALO from other than that created by providing the enzyme for the co-formulation. I'm thinking it won't produce any royalties or such, but I could be wrong. What are your thoughts about that?
China approval was a positive news item; as is the ARG-117, which, it must be noted, is still in Phase I according to HALO's slide presentation.
ARGX, at least, is going to keep the lights on at Halozyme for a while.

Due to the unexpected wins in the IP front, I expect multiple new deals to come in short order and announced in a series of PR's and, if I'm correct, this will light the candle and propel us to substantial new highs.
Of course, continued failure to deliver these will, in time, erode the confidence of investors and the PPS will start to reflect the limited upside of the current pipeline.
Time will tell.

We've bounced back due to IP wins and interest rate predictions, but current PPS is more than $5 shy of all time highs set over a year and a half ago.
Money managers are waiting for new deals, and that's the bottom line, IMHO.
Good luck to us all.
👍️ 1
maumar maumar 6 days ago
Efga SC was approved in China yesterday. And we got one more positive surprise at Argenex's R&D day. From JPM:

"We note that if the company were to successfully deliver on the 2030 Vision of addressing 50k patients (vs. 10k patients at present, already annulising at Revenues of c.$1.7bn), at Vyvgart-like pricing, this would imply at least a c.$8.7bn topline in 2030. This would be c.30% above 2030 Bloomberg consensus Revenues of $6.7bn, with far bigger upside beyond 2030, given how early many of the pipeline opportunities would be in their launches."

ARGX has another Enhanze product in development: ARGX-117/empa, which they called another "pipeline-in-a-product."

Obviously, getting the co-formulation patent for Efga SC that would guarantee royalties to Halo until 2040 will make a big difference. Another positive surprise (new deals, Darzalex SC US patent grant, co-formulation patents...) will probably take us to new highs.
👍️ 3
biotechinvestor1 biotechinvestor1 6 days ago
Glad you are still here and have not given up. It gives me more reassurance that we are not at a top.

Sometimes permabear (yes, I know you claim you are not one) capitulation signals a top. Glad you are still here and trying to say that halo run is insignificant (your last post).

For folks who have been here on this board since 2023 or care to go back and read your posts, they will know your bearishness (despite claiming you own shares) since we were in low 30’s.

Many of us longs pointed to the amazing fundamentals and steadfastly posted about buying on the dips. As predicted by some of us, the stock has risen from low 30’s to the current levels DESPITE A SINGLE NEW DEAL. Of course we congratulate ourselves for making the right choice despite the shortsighted bearish views on this board.

👍️ 2
easycomeandgo easycomeandgo 6 days ago
OK…, I was never a bear on this stock… I thought I posted about that, maybe not clearly enough for some. I continue to hold a very few thousand shares which will not go long term until Oct. 25, unfortunately. But, I am glad that they are moving up, rather than down. With the market up like it was yesterday and with the rotation, there were quite a few 52 week highs. https://www.wsj.com/market-data/stocks/newfiftytwoweekhighsandlows There are many people congratulating themselves for being geniuses. Hehe. All in all, I am not dissatisfied with my buy/sell decisions. I am the only person I need to please, when it comes to that. I am amazed that there exist people I don’t even know, and who don’t know me, apparently deriving satisfaction from imagining otherwise. Be my guest. Good luck to all. Cheers.
👍️0
biotechinvestor1 biotechinvestor1 7 days ago
Another 52 week high. Where is EasyComeEasyGo?

Come back and tell us how you were never a bear on this stock and how you timed your moves perfectly ;)
👍️ 3
stockrafter stockrafter 7 days ago
To answer a question from the past, with today's example.......

It took took a little over 3 yrs, 2 mns to go from filing to patent......

https://www.freepatentsonline.com/12037618.html

Publication Date: 07/16/2024
Filing Date: 05/21/2021

Will give 20 years for the specific new claims in the new patent, following the long family of similar patents, which were posted earlier.........

"PH20 polypeptide variants, formulations and uses thereof "
👍️ 2
OncoJock OncoJock 1 week ago
Thank you for sharing your thoughts and perspectives.

As I reflect on this more, I'm thinking perhaps it has to do with the very high degree of institutional ownership. (See attached.) Apparently people like us, retail shareholders, hold only a tiny minority (0.8%) of outstanding shares. I'm guessing institutions take time to make investment decisions, do not act quickly or try to time the market. But that's just a guess.

Good luck to you.

-- OJ
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Halo’s fundamentals and valuations are absolutely the envy of most. Its share price will continue to do well for the next several years.

Having said this, I am disappointed that Helen has still not delivered on 2 out of the 3 partnerships she guided for 2023. We are almost 7 months into 2024 and still nothing.

The second thing that is irritating is that they seem to be gearing up for an acquisition sooner than I had hoped for. I say this because of the new job posting for an executive director of M&A on halo’s website.

In my view, they need to get a few more Enhanze partnerships before they buy another company.
👍️ 2
stockrafter stockrafter 2 weeks ago
Agree both are interesting and worth skimming thru.......

Not sure where the obesity connection will go, but in these days of over consumption, anytime a drug is connected to "obesity," "an intervention" and "a novel therapeutic strategy," an investor needs to take notice.....

With the consortium connection, one would think there would be more info out there on upcoming HVAI deals by now...........

https://subcutaneousconsortium.org/membership-overview/
👍️ 1
OncoJock OncoJock 2 weeks ago
Thank you for sharing your perspective.
👍️0
maumar maumar 2 weeks ago
I would guess there are several reasons.

First of all, Halo is not a small-cap stock. Several other mid-cap and large biotechs didn’t participate (Asnd, Argx and others.)

Second, Halo is up 55% from six months ago and, for better or worse, is not the type of biotech that can make huge moves up or down overnight. It is a lower risk/lower reward stock than many other biotechs.

Third, the stock peaked around $50, $54 and then $59 in 2021 and 2022. In 2022, Halo sold convertible notes that have a conversion price of $56. Because of all of the above, the stock has a lot of resistance in this area.
👍️ 3
Howeeme Howeeme 2 weeks ago
Halo beats to its own drum. Institutions own most of it and traders play with it. Fundamentals are great and that drives the price. It’s going to go much higher sooner than later. Last time it made highs a few years ago the price dropped over 30 percent very quickly. This time it’s holding tight.
👍️ 3
OncoJock OncoJock 2 weeks ago
Does anyone have any theories as to why . . .

HALO did not participate in today's strong rally that drove the price of so many small caps upward?

According to the Wall Street Journal, today the Russell 2000 index of small-cap stocks soared 3.6% in its best day since November. Some of my other small biotech stocks (I own half a dozen) jumped 5, 7, even 9%. Every darned holding in my brokerage list (roughly 14) was green EXCEPT for HALO, which was in the red, down slightly.

This defies logic, in my world. The company is becoming a cash cow. We've been held hostage, or so I thought, by the stubbornly high yield on the 10-year Treasury. But even when the 10-year yield dropped sharply today, the HALO price did not budge.

I'd be interested in what other shareholders on this board think might be the reason HALO did not participate in today's strong small-cap rally.

-- OJ

P.S. Even my utilities ETF advanced!
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Nice finds. Both links are interesting.
👍️0
stockrafter stockrafter 2 weeks ago
Shhh, its all a secret…..

Acknowledgement: PEGPH20 is an in-kind gift from Halozyme Therapeutics, Inc under a Material Transfer Agreement.
https://www.biorxiv.org/content/10.1101/2024.06.22.600183v1.full.pdf

This consortium is actually mentioned in the HVAI filing…..
https://subcutaneousconsortium.org/news-and-events/
👍️ 2
maumar maumar 2 weeks ago
I also don't think it was a sector thing. There was quite a bit of churn yesterday, even today volume was a bit higher than average and Halo was weaker than the sector. It may just be that there is a lot of resistance in this area and the stock is consolidating. Also, I am sure some investors are skeptical that there will be more positive surprises or new deals soon. Time will tell.
👍️ 1
OncoJock OncoJock 2 weeks ago
Got it, thanks.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Talking about full year 2024 PE.

If we end 2024 at the same PE we ended 2023, we will be in the $70-80 range, simply because the E (earnings) has gone up so much.

Here is the full 2023 and 2024 PE ratios:

https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

👍️ 1
OncoJock OncoJock 2 weeks ago
Not to my knowledge, but it's hard to keep all of our many customers straight. (That's a good problem to have.)
👍️0
OncoJock OncoJock 2 weeks ago
sorry no clue
👍️0
OncoJock OncoJock 2 weeks ago
Agree with this perspective, thanks for sharing.

When you talk about P/E, are you thinking trailing 12 months (TTM) or forward 12 months (FY)? As I'm sure you know, these can be very different numbers.

-- oj
👍️0
MysticalGladiator72 MysticalGladiator72 2 weeks ago
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

https://finance.yahoo.com/news/invested-1000-halozyme-therapeutics-decade-123003402.html
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
Agreed
👍️0
biotecholdguy biotecholdguy 2 weeks ago
Besides making a profit...Think about the millions of sick people that get to be helped by HALO !!
so awesome.
👍️ 3
biotechinvestor1 biotechinvestor1 2 weeks ago
Unlikely that it was a sector thing.

1) XBI did not have a reversal in the second half of day like halo did

2) halo’s volume was unusually high

3) halo reached another 52 week high

Who knows what a single day of trading is all about. It’s the trend and fundamentals that matter.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
I think it was a sector thing. Had similar moves in other biotech stocks. There was some indication of a likely Fed move to lower interest rates and that usually creates a nice bump in the space. Just a guess, though.
👍️0
bleedpurple bleedpurple 2 weeks ago
Maybe some big boy shorts closing out and going long w MM help? Halo pretty highly shorted. I’m glad to be long right now.
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
No idea.
👍️0
maumar maumar 2 weeks ago
What do you make of the stock action today?
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
been in Halozyme since 2011. Back then, I bought once or twice a year as this was a speculative investment (PEGPH20) with the back up plan of Enhanze.

I started buying on a regular basis since they became profitable and the P/E ratio and Peg were/are super attractive.

In my retirement account I purchase halo 3 times a year. In my taxed account I buy on a weekly basis and more on the dips.

I am in a handful of other profitable, high profit margin, reasonable value stocks, but the rest of my portfolio is in index funds.

Valuations and fundamentals are like gravity. Mr. market can only defy them for a limited time. Halozyme is profitable and it’s profits are growing. The share prices will go up overtime no matter what. My strategy is simple. Buy and hold for as long as the PE ratio and the peg are below industry averages, and comps.

I don’t see myself selling until Peg is above 1.2 and PE ratio is above 27. We are far from both.
👍️ 4
maumar maumar 2 weeks ago
Just curious what your strategy is. Do you add just a few shares at a time? What is your average cost per share in your position?
👍️0
biotechinvestor1 biotechinvestor1 2 weeks ago
loving the dips. Thank you, Mr. Market for the opportunity to accumulate.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
That was my impression, Howee. I was wondering why the other poster was asking about it.
👍️0
Howeeme Howeeme 2 weeks ago
It does not and neither does methotrexate. Just commenting on the AI and the experience for the patient.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 weeks ago
Are you contending that subcu Dupixent contains hyaluronidase?
👍️0
Roger1 Roger1 2 weeks ago
Thank you for this. Perhaps Dupixent should be looking at us for their AI. That should be an easy sell for HALO.
👍️0
Howeeme Howeeme 2 weeks ago
Don’t really know the biology of Dupixent but I have family that uses Dupixent and Methtrexate both using Auto Injectors. Halozyme produces the Methtrexate AI and it goes very smoothly. The Dupixent AI is very painful and hard to handle.
👍️ 2
Roger1 Roger1 2 weeks ago
Wonder where Sanofi got the molecule for subq Dupixent used in copd trials. Any thoughts?
👍️0
Roger1 Roger1 2 weeks ago
Are we supplying Hylenex for Dupixent? Memory slipping...
👍️0
OncoJock OncoJock 2 weeks ago
This looks very interesting: 3 Halozyme employees rubbing shoulders in a professional context for half a day with employees from Roche, Sanofi, Lilly, Merck, AZ, and Novartis. Roche is already a repeat customer of Halozyme's, while Sanofi, Lilly, Merck, AZ and Novartis are all prospective customers. With no sign of any Halozyme competitors present among the presenters. How can this not be a wonderful thing for Halozyme???

👍️ 1
stockrafter stockrafter 2 weeks ago
https://2024crsannualmeeting.eventscribe.net/agenda.asp?pfp=days&day=7/8/2024&theday=Monday&h=Monday%20July%208&BCFO=P%7CG

Hoping for some deals for the effort.......
👍️ 2
halofan halofan 2 weeks ago
Ok, thanks for the explanation. HALO, unlike those other companies, has earned the right to be the darling of social media!!
👍️0

Your Recent History

Delayed Upgrade Clock